Online inquiry

IVTScrip™ mRNA-Anti-S, AZD8895(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3446MR)

This product GTTS-WQ3446MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, AZD8895(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3446MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1985MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AGS-22CE
GTTS-WQ12054MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ954MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-323
GTTS-WQ6437MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CT-P22
GTTS-WQ4855MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BT-062
GTTS-WQ10909MR IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MABT5102A
GTTS-WQ7845MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ15008MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW